» Articles » PMID: 24356582

Poly(ADP-ribose) Binding to Chk1 at Stalled Replication Forks is Required for S-phase Checkpoint Activation

Overview
Journal Nat Commun
Specialty Biology
Date 2013 Dec 21
PMID 24356582
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Damaged replication forks activate poly(ADP-ribose) polymerase 1 (PARP1), which catalyses poly(ADP-ribose) (PAR) formation; however, how PARP1 or poly(ADP-ribosyl)ation is involved in the S-phase checkpoint is unknown. Here we show that PAR, supplied by PARP1, interacts with Chk1 via a novel PAR-binding regulatory (PbR) motif in Chk1, independent of ATR and its activity. iPOND studies reveal that Chk1 associates readily with the unperturbed replication fork and that PAR is required for efficient retention of Chk1 and phosphorylated Chk1 at the fork. A PbR mutation, which disrupts PAR binding, but not the interaction with its partners Claspin or BRCA1, impairs Chk1 and the S-phase checkpoint activation, and mirrors Chk1 knockdown-induced hypersensitivity to fork poisoning. We find that long chains, but not short chains, of PAR stimulate Chk1 kinase activity. Collectively, we disclose a previously unrecognized mechanism of the S-phase checkpoint by PAR metabolism that modulates Chk1 activity at the replication fork.

Citing Articles

All-trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin.

Mei B, Li J, Wang D, Feng L, Huang J, Zhang G Mol Cancer Ther. 2024; 24(3):453-463.

PMID: 39676352 PMC: 11876957. DOI: 10.1158/1535-7163.MCT-24-0140.


PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.

Ravindranathan R, Somuncu O, da Costa A, Mukkavalli S, Lamarre B, Nguyen H Proc Natl Acad Sci U S A. 2024; 121(47):e2413954121.

PMID: 39546575 PMC: 11588084. DOI: 10.1073/pnas.2413954121.


Poly-ADP-ribosylation dynamics, signaling, and analysis.

Al-Rahahleh R, Sobol R Environ Mol Mutagen. 2024; 65(9):315-337.

PMID: 39221603 PMC: 11604531. DOI: 10.1002/em.22623.


Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.

Kulkarni S, Gajjar K, Madhusudan S Front Oncol. 2024; 14:1414112.

PMID: 39135999 PMC: 11317305. DOI: 10.3389/fonc.2024.1414112.


Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.

Saville K, Al-Rahahleh R, Siddiqui A, Andrews M, Roos W, Koczor C DNA Repair (Amst). 2024; 140:103700.

PMID: 38897003 PMC: 11239280. DOI: 10.1016/j.dnarep.2024.103700.